Novel approaches towards designing of isoform-selective inhibitors against class II histone deacetylases: The acute requirement for targetted anticancer therapy

Current Topics in Medicinal Chemistry

Volumn 16, Issue 22, 2016, Pages 2441-2452

  Ganai, Shabir Ahmad ^a  

^a SHER E KASHMIR UNIVERSITY OF AGRICULTURAL SCIENCES AND TECHNOLOGY OF KASHMIR   (India)

Author keywords

Cancer; Histone deacetylase inhibitors; Histone deacetylases; Isoform selective inhibitors; Pan inhibitors

Indexed keywords

BELINOSTAT; ENTINOSTAT; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; NUCLEAR RECEPTOR COREPRESSOR; PANOBINOSTAT; ROMIDEPSIN; TRICHOSTATIN A; TUBACIN; VALPROIC ACID; VORINOSTAT; ZINC BINDING PROTEIN; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; ISOENZYME;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW DEPRESSION; CELL CYCLE ARREST; CHROMATIN CONDENSATION; COMPUTER MODEL; CUTANEOUS T CELL LYMPHOMA; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; HEART ARRHYTHMIA; MOLECULAR DOCKING; NERVE DEGENERATION; OXIDATIVE STRESS; PERIPHERAL T CELL LYMPHOMA; PHARMACOPHORE; UPREGULATION; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; ISOENZYMES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84978971774     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160212122609     Document Type: Article

References (75)

1. Luger, K.; Mader, A. W.; Richmond, R. K.; Sargent, D. F.; Richmond, T. J., Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389 (6648), 251-60.
2. Bannister, A. J.; Kouzarides, T., Regulation of chromatin by histone modifications. Cell.Res, 2011, 21 (3), 381-395.
3. Zhang, Y.; Reinberg, D., Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes.Dev, 2001, 15 (18), 2343-60.
4. Nowak, S. J.; Corces, V. G., Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends. Genet, 2004, 20 (4), 214-20.
5. Weake, V. M.; Workman, J. L., Histone ubiquitination: triggering gene activity. Nat. Rev. Mol. Cell, 2008, 29 (6), 653-63.
6. Kurdistani, S. K.; Grunstein, M., Histone acetylation and deacetylation in yeast. Mol. Cell. Biol, 2003, 4 (4), 276-84.
7. Ganai S.A.; Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Arch. Pharm. Res., 2015: 1-11.
8. Ropero, S.; Esteller, M., The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol, 2007, 1 (1), 19-25.
9. Rivieccio, M. A.; Brochier, C.; Willis, D. E.; Walker, B. A.; D’Annibale, M. A.; McLaughlin, K.; Siddiq, A.; Kozikowski, A. P.; Jaffrey, S. R.; Twiss, J. L.; Ratan, R. R.; Langley, B., HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (46), 19599-604.
10. de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg, A. B., Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J, 2003, 370 (Pt 3), 737-49.
11. Ganai S. A.; In Silico Approaches Towards Safe Targeting of Class I Histone Deacetylases. Molecular Life Sciences, 2015, p. 1-9.
12. Vega, R. B.; Harrison, B. C.; Meadows, E.; Roberts, C.R.; Papst, P.J.; Olson, E.N.; Timothy, A. McKinsey., Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol, 2004, 24, 8374-85.
13. Passier, R.; Zeng, H.; Frey, N.; Naya, F. J.; Nicol R.L.; McKinsey, T. A.; Overbeek, P.; Richardson, J.A.; Grant, S.R,; Olson, E.N., CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest., 2000, 105, 1395-406.
14. Ganai S. A.; HDAC Inhibitors Entinostat and Suberoylanilide Hydroxamic Acid (SAHA): The Ray of Hope for Cancer Therapy. Molecular Life Sciences, 2015.
15. Haberland, M.; Montgomery, R.L.; Olson, E.N.; The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet, 2009, 10 (1), 32-42.
16. Ganai, S. A., Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity. Curr. Top. Med. Chem., 2016, 16 (4), 427-34.
17. Lu, J.; McKinsey T. A.; Zhang C.L.; Olson, E.N., Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol. Cell 2000, 6, 233-44.
18. Corpet, F., Multiple sequence alignment with hierarchical clustering. Nucleic. Acids. Res 1988, 16, 10881-90.
19. Zhang, C. L.; McKinsey, T.A.; Chang, S.; Antos, C.L.; Hill, J.A.; Olson, E.N., Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110, 479-88.
20. Chang, S.; McKinsey, T.A.; Zhang, C.L.; Richardson, J.A.; Hill, J.A.; Olson, E.N., Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol, 2004, 24, 8467-76.
21. Vega, R.B.; Matsuda, K.; Oh, J.; Barbosa, A. C.; Yang, X.; Meadows, E, McAnally, J.; Pomajzl, C.; Shelton, J.M.; Richardson, J.A.; Karsenty, G.; Olson, E.N.; Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 2004, 119, 555-66.
22. Chang, S.; Young, B.D.; Li, S.; Qi, X.; Richardson, J.A.; Olson, E.N.; Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126, 321-34.
23. Fischle, W.; Dequiedt, F.; Hendzel, M.J.; Guenther, M.G.; Lazar, M.A.; Voelter, W.; Verdin, E., Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell, 2002, 9, 45-57.
24. Zhang, C.L.; McKinsey, T.A.; Lu, J.R.; Olson, E.N., Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J. Biol. Chem, 2001, 276, 35-9.
25. Zhang, C.L.; McKinsey, T.A.; Olson, E.N., Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell. Biol, 2002, 22, 7302-12.
26. Bottomley, M.J.; Lo, Surdo. P.; Di, Giovine. P.; Cirillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De, Francesco. R.; Steinkühler, C.; Gallinari, P.; Carfí, A., Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem., 2008, 283, 26694-704.
27. Jones, P.; Altamura, S.; De Francesco, R.; Gallinari, P.; Lahm, A.; Neddermann, P.; Rowley, M.; Serafini, S.; Steinkühler, C., Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg. Med. Chem. Lett, 2008, 18, 1814-9.
28. Glass, C.K.; Rosenfeld, M.G.; The coregulator exchange in transcriptional functions of nuclear receptors. Genes. Dev, 2000, 14: 121-41.
29. Jones, P.L.; Veenstra, G. J.; Wade, P. A.; Vermaak, D.; Kass, S.U.; Landsberger, N.; Strouboulis, J.; Wolffe, A.P., Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet, 1998, 19, 187-91.
30. Nan, X.; Ng, H.H.; Johnson, C.A.; Laherty, C.D.; Turner, B.M.; Eisenman, R.N, Bird, A., Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393, 386-9.
31. Jayathilaka, N.; Han, A.; Gaffney, K.J.; Dey, R.; Jarusiewicz, J.A.; Noridomi, K.; Philips, M.A.; Lei, X.; He, J.; Ye, J.; Gao, T.; Petasis, N.A.; Chen, L., Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2. Nucleic. Acids. Res, 2012, 40, 5378-88.
32. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T., Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem, 1993, 268(30), 22429-35.
33. Bhuiyan MP, Kato T, Okauchi T, Nishino N, Maeda S, Nishino TG, et al. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg. Med. Chem, 2006,14, 3438-46.
34. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P., Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401 (6749), 188-93.
35. Ganai, S. A.; Shanmugam, K.; Mahadevan, V., Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms. J. Biomol. Struct. Dyn, 2015, 33 (2), 374-387.
36. Mottamal, M.; Zheng, S.; Huang, T. L.; Wang, G., Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules, 2015, 20 (3), 3898-941.
37. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J. W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M., Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J, 2008, 409 (2), 581-9.
38. Miller, T. A.; Witter, D. J.; Belvedere, S., Histone deacetylase inhibitors. J.Med.Chem, 2003, 46 (24), 5097-116.
39. Jung, M.; Brosch, G.; Kolle, D.; Scherf, H.; Gerhauser, C.; Loidl, P., Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med.Chem, 1999, 42 (22), 4669-79.
40. Noureen, N.; Rashid, H.; Kalsoom, S., Identification of typespecific anticancer histone deacetylase inhibitors: road to success. Cancer. Chemother. Pharmacol, 2010, 66 (4), 625-33.
41. Cao, D. J.; Wang, Z. V.; Battiprolu, P. K.; Jiang, N.; Morales, C. R.; Kong, Y.; Rothermel, B. A.; Gillette, T. G.; Hill, J. A., Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(10), 4123-8.
42. Zhang, C. Z.; Zhang, H. T.; Chen, G. G.; Lai, P. B., Trichostatin A sensitizes HBx-expressing liver cancer cells to etoposide treatment. Apoptosis, 2011, 16 (7), 683-95.
43. Shao, Y.; Gao, Z.; Marks, P. A.; Jiang, X., Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (52), 18030-5.
44. Galmozzi, A.; Mitro, N.; Ferrari, A.; Gers, E.; Gilardi, F.; Godio, C.; Cermenati, G.; Gualerzi, A.; Donetti, E.; Rotili, D.; Valente, S.; Guerrini, U.; Caruso, D.; Mai, A.; Saez, E.; De Fabiani, E.; Crestani, M., Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes 2013, 62 (3), 732-42.
45. Colussi, C.; Mozzetta, C.; Gurtner, A.; Illi, B.; Rosati, J.; Straino, S.; Ragone, G.; Pescatori, M.; Zaccagnini, G.; Antonini, A.; Minetti, G.; Martelli, F.; Piaggio, G.; Gallinari, P.; Steinkuhler, C.; Clementi, E.; Dell’Aversana, C.; Altucci, L.; Mai, A.; Capogrossi, M. C.; Puri, P. L.; Gaetano, C., HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (49), 19183-7.
46. Jones, J.; Juengel, E.; Mickuckyte, A.; Hudak, L.; Wedel, S.; Jonas, D.; Blaheta, R. A., The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J.Cell. Mol. Med, 2009, 13 (8b), 2376-85.
47. Johannessen, C. U.; Johannessen, S. I., Valproate: past, present, and future. CNS. Drug. Rev, 2003, 9 (2), 199-216.
48. Ganai, S. A.; Kalladi, S. M.; Mahadevan, V., HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. J. Biomol.Struct. Dyn, 2015, 33 (6), 1185-97.
49. Gibbs, A.; Schwartzman, J.; Deng, V.; Alumkal, J., Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (39), 16663-8.
50. Ververis, K.; Hiong, A.; Karagiannis, T. C.; Licciardi, P. V., Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics, 2013, 7, 47-60.
51. Chun, P., Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch.Pharm. Res, 2015, 38 (6), 933-49.
52. Sakuma, T.; Uzawa, K.; Onda, T.; Shiiba, M.; Yokoe, H.; Shibahara, T.; Tanzawa, H., Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol, 2006, 29 (1), 117-24.
53. Shan, B.; Yao, T. P.; Nguyen, H. T.; Zhuo, Y.; Levy, D. R.; Klingsberg, R. C.; Tao, H.; Palmer, M. L.; Holder, K. N.; Lasky, J. A., Requirement of HDAC6 for transforming growth factor-beta1- induced epithelial-mesenchymal transition. J. Biol. Chem, 2008, 283 (30), 21065-73.
54. Ozdag, H.; Teschendorff, A. E.; Ahmed, A. A.; Hyland, S. J.; Blenkiron, C.; Bobrow, L.; Veerakumarasivam, A.; Burtt, G.; Subkhankulova, T.; Arends, M. J.; Collins, V. P.; Bowtell, D.; Kouzarides, T.; Brenton, J. D.; Caldas, C., Differential expression of selected histone modifier genes in human solid cancers. BMC. Genomics, 2006, 7, 90.
55. Milde, T.; Oehme, I.; Korshunov, A.; Kopp-Schneider, A.; Remke, M.; Northcott, P.; Deubzer, H. E.; Lodrini, M.; Taylor, M. D.; von Deimling, A.; Pfister, S.; Witt, O., HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin. Cancer Res, 2010, 16 (12), 3240-52.
56. Lachenmayer, A.; Toffanin, S.; Cabellos, L.; Alsinet, C.; Hoshida, Y.; Villanueva, A.; Minguez, B.; Tsai, H. W.; Ward, S. C.; Thung, S.; Friedman, S. L.; Llovet, J. M., Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol, 2012, 56 (6), 1343-50.
57. Ouaissi, M.; Sielezneff, I.; Silvestre, R.; Sastre, B.; Bernard, J. P.; Lafontaine, J. S.; Payan, M. J.; Dahan, L.; Pirro, N.; Seitz, J. F.; Mas, E.; Lombardo, D.; Ouaissi, A., High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann. Surg. Oncol, 2008, 15 (8), 2318-28.
58. Moreno, D. A.; Scrideli, C. A.; Cortez, M. A.; de Paula Queiroz, R.; Valera, E. T.; da Silva Silveira, V.; Yunes, J. A.; Brandalise, S. R.; Tone, L. G., Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. British.J.Haematol, 2010, 150 (6), 665-73.
59. Barneda-Zahonero, B.; Parra, M., Histone deacetylases and cancer. Mol. Oncolol, 2012, 6 (6), 579-589.
60. Wang, J. C.; Kafeel, M. I.; Avezbakiyev, B.; Chen, C.; Sun, Y.; Rathnasabapathy, C.; Kalavar, M.; He, Z.; Burton, J.; Lichter, S., Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011, 81 (5-6), 325-9.
61. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I., HDAC family: What are the cancer relevant targets? Cancer. Lett, 2009, 277 (1), 8-21.
62. Bruserud, O.; Stapnes, C.; Ersvaer, E.; Gjertsen, B. T.; Ryningen, A., Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr. Pharm.Biotechnol, 2007, 8 (6), 388-400.
63. Bieliauskas, A. V.; Pflum, M. K. H., Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev, 2008, 37 (7), 1402-1413.
64. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (8), 4389-94.
65. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G., Class II (IIa)- selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J.Med.Chem, 2005, 48 (9), 3344-53.
66. Di Micco, S.; Chini, M. G.; Terracciano, S.; Bruno, I.; Riccio, R.; Bifulco, G., Structural basis for the design and synthesis of selective HDAC inhibitors. Bioorg.Med.Chem, 2013, 21 (13), 3795-807.
67. Mai, A.; Jelicic, K.; Rotili, D.; Di Noia, A.; Alfani, E.; Valente, S.; Altucci, L.; Nebbioso, A.; Massa, S.; Galanello, R.; Brosch, G.; Migliaccio, A. R.; Migliaccio, G., Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol.Pharmacol, 2007, 72 (5), 1111-23.
68. Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M., Subtype selective substrates for histone deacetylases. J.Med. Chem, 2004, 47 (21), 5235-43.
69. Suzuki, T.; Kouketsu, A.; Itoh, Y.; Hisakawa, S.; Maeda, S.; Yoshida, M.; Nakagawa, H.; Miyata, N., Highly potent and selective histone deacetylase 6 inhibitors designed based on a smallmolecular substrate. J.Med.Chem, 2006, 49 (16), 4809-12.
70. Brown M, et al. US20100317739. 2010.
71. Kong, Y.; Jung, M.; Wang, K.; Grindrod, S.; Velena, A.; Lee, S. A.; Dakshanamurthy, S.; Yang, Y.; Miessau, M.; Zheng, C.; Dritschilo, A.; Brown, M. L., Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor. Mol. Cancer. Ther, 2011, 10 (9), 1591-9.
72. Ononye, S. N.; van Heyst, M.; Falcone, E. M.; Anderson, A. C.; Wright, D. L., Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharm.Pat. Anal, 2012, 1 (2), 10.4155/ppa.12.21.
73. Merck & Co. US20090156591. 2009.
74. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J., Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug. Discov, 2004, 3 (11), 935-949.
75. Salam, N. K.; Nuti, R.; Sherman, W., Novel method for generating structure-based pharmacophores using energetic analysis. J. Chem. Inf. Model, 2009, 49 (10), 2356-68.